Date: 2016-10-26
Type of information: Publication of results in a medical journal
phase: preclinical
Announcement: publication of results in the Proceedings of the National Academy of Sciences of the United States of America (PNAS)
Company: F2G (UK)
Product: F901318 (2-(1,5-dimethyl-3-phenyl-1H-pyrrol-2-yl)-N-{4-[4-(5-fluoro-pyrimidin-2-yl)piperazin-1-yl]- phenyl}-2-oxo-acetamide)
Action
mechanism: enzyme inhibitor/dihydroorotate dehydrogenase (DHODH) inhibitor. F901318 belongs to a new class of antifungal agents called the orotomides. This new class has been discovered and developed by F2G. The orotomides are active against Aspergillus and other rare and resistant moulds and act via a completely different mechanism than currently marketed antifungal agents. They inhibit dihydroorotate dehydrogenase (DHODH).
Disease: aspergillosis
Therapeutic area: Infectious diseases
Country:
Trial details:
Latest
news: * On October 26, 2016, F2G, a UK-based antifungal drug discovery and development company, announced the publication of the initial F901318 data in the Proceedings of the National Academy of Sciences (PNAS), of their work in elucidating the mechanism of action of its novel orotomide antifungal – lead candidate F901318. (“F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase” - abstract). The identification of dihydroorotate dehydrogenase (DHODH) as the mechanism by which F901318 inhibits and kills Aspergillus fumigatus was a major breakthrough differentiating F901318 from all other systemic antifungal agents. DHODH represents one of only a handful of clinically validated antifungal drug targets. The paper describes the genetic and biochemical techniques used to identify and conclusively confirm DHODH as the target of F901318 and also the in vivo activity of the drug in severe infection models. F2G plans to advance its lead compound, F901318 to completion of a pivotal registration study, and to further develop earlier stage assets in its pipeline.
